Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 47,507 shares, an increase of 1,454.0% from the April 30th total of 3,057 shares. Based on an average trading volume of 651,410 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy”.

Daiichi Sankyo Price Performance

OTCMKTS DSNKY traded down $0.08 during mid-day trading on Friday, hitting $16.82. The stock had a trading volume of 188,408 shares, compared to its average volume of 431,731. Daiichi Sankyo has a 52-week low of $15.56 and a 52-week high of $27.50. The company has a market cap of $31.86 billion, a price-to-earnings ratio of 17.89, a P/E/G ratio of 1.20 and a beta of -0.25. The company has a 50 day simple moving average of $17.44 and a 200 day simple moving average of $19.60. The company has a quick ratio of 1.85, a current ratio of 2.69 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Equities analysts forecast that Daiichi Sankyo will post 0.91 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.